GENEVA, SWITZERLAND — June 2025
In a move signaling the rise of a new global player in the startup ecosystem, CapitalConnect has officially secured its first cross-border funding deal — a €120,000 investment closed in Geneva between French medtech startup Biogenix Santé and Swiss investor group Aurèle Capital.
What began as an ambitious platform designed to bridge the gap between founders and investors is now proving it can operate on an international stage. With 44 startups, 9 investors, and over 500,000 in total deal volume to date, CapitalConnect is no longer just a scrappy early-stage platform — it’s becoming a real force in global venture matchmaking.
“This deal isn’t just a win for Biogenix and Aurèle Capital,” said founder Yeshaya Shulevitz, who delivered the announcement in French onstage in Geneva. “It’s proof that CapitalConnect works — that we’re building something that transcends borders and unlocks real opportunities.”
Launched just five months ago, the platform has already gained traction in seven countries, with monthly active users climbing past 15,000. The Geneva milestone represents more than just a funding round — it’s a signal that emerging founders across Europe are starting to see CapitalConnect as a viable tool to accelerate growth, visibility, and capital access.
As the company eyes further expansion into the U.K., Israel, and the U.S. west coast, this deal could mark the first of many cross-border collaborations sparked through the platform.
"Geneva was just the beginning."
Comments
Leave a Comment